Free Trial

Bioventus (BVS) Competitors

Bioventus logo
$6.40 -0.07 (-1.08%)
Closing price 04:00 PM Eastern
Extended Trading
$6.40 +0.00 (+0.08%)
As of 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BVS vs. EYE, LMAT, NVCR, SSII, ENOV, CNMD, CDRE, AORT, LQDA, and ESTA

Should you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include National Vision (EYE), LeMaitre Vascular (LMAT), NovoCure (NVCR), SS Innovations International (SSII), Enovis (ENOV), CONMED (CNMD), Cadre (CDRE), Artivion (AORT), Liquidia Technologies (LQDA), and Establishment Labs (ESTA). These companies are all part of the "medical equipment" industry.

Bioventus vs. Its Competitors

National Vision (NASDAQ:EYE) and Bioventus (NYSE:BVS) are both medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

National Vision has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.

62.9% of Bioventus shares are held by institutional investors. 2.7% of National Vision shares are held by company insiders. Comparatively, 33.0% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

National Vision has a net margin of -1.40% compared to Bioventus' net margin of -7.11%. Bioventus' return on equity of 15.61% beat National Vision's return on equity.

Company Net Margins Return on Equity Return on Assets
National Vision-1.40% 3.44% 1.40%
Bioventus -7.11%15.61%4.01%

National Vision has higher revenue and earnings than Bioventus. National Vision is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
National Vision$1.82B1.10-$28.50M-$0.33-76.79
Bioventus$567.70M0.93-$156.23M-$0.48-13.33

National Vision presently has a consensus target price of $23.00, suggesting a potential downside of 9.23%. Bioventus has a consensus target price of $13.75, suggesting a potential upside of 114.84%. Given Bioventus' stronger consensus rating and higher possible upside, analysts clearly believe Bioventus is more favorable than National Vision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
National Vision
0 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.56
Bioventus
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

In the previous week, National Vision had 10 more articles in the media than Bioventus. MarketBeat recorded 11 mentions for National Vision and 1 mentions for Bioventus. Bioventus' average media sentiment score of 1.68 beat National Vision's score of 1.02 indicating that Bioventus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
National Vision
4 Very Positive mention(s)
4 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Bioventus
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

National Vision and Bioventus tied by winning 8 of the 16 factors compared between the two stocks.

Get Bioventus News Delivered to You Automatically

Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BVS vs. The Competition

MetricBioventusSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$525.72M$65.66M$5.70B$21.15B
Dividend YieldN/AN/A4.59%3.58%
P/E Ratio-10.496.0527.9027.76
Price / Sales0.93142.51442.1958.69
Price / Cash12.5818.4136.5523.00
Price / Book2.297.348.634.67
Net Income-$156.23M-$25.32M$3.24B$993.85M
7 Day Performance-1.39%1.79%3.22%1.16%
1 Month Performance-5.33%6.08%10.72%4.99%
1 Year Performance-14.21%56.17%34.94%12.54%

Bioventus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BVS
Bioventus
3.3714 of 5 stars
$6.40
-1.1%
$13.75
+114.8%
-14.4%$525.72M$567.70M-10.491,200Positive News
EYE
National Vision
2.8177 of 5 stars
$25.31
+0.9%
$22.10
-12.7%
+91.6%$1.98B$1.82B-76.6913,411Positive News
Analyst Forecast
LMAT
LeMaitre Vascular
2.7232 of 5 stars
$79.82
+0.1%
$97.83
+22.6%
-8.8%$1.80B$219.86M40.29490Analyst Forecast
NVCR
NovoCure
3.7908 of 5 stars
$16.10
+0.5%
$32.43
+101.4%
-12.0%$1.79B$605.22M-10.661,488News Coverage
Earnings Report
SSII
SS Innovations International
N/A$8.40
+5.9%
N/AN/A$1.54B$20.65M0.004Gap Up
ENOV
Enovis
2.9296 of 5 stars
$26.35
+0.2%
$55.60
+111.0%
-39.8%$1.50B$2.11B8.377,367News Coverage
High Trading Volume
CNMD
CONMED
4.7324 of 5 stars
$47.78
+0.3%
$62.20
+30.2%
-31.5%$1.47B$1.31B12.573,900Upcoming Earnings
CDRE
Cadre
3.3526 of 5 stars
$32.27
-1.1%
$37.50
+16.2%
-12.3%$1.33B$567.56M34.362,284Positive News
Dividend Announcement
AORT
Artivion
2.9247 of 5 stars
$30.63
+0.5%
$32.40
+5.8%
+11.8%$1.30B$388.54M121.961,600News Coverage
LQDA
Liquidia Technologies
3.2872 of 5 stars
$15.10
+3.9%
$26.89
+78.1%
+53.7%$1.24B$14M-9.5650News Coverage
ESTA
Establishment Labs
2.0728 of 5 stars
$42.60
+2.5%
$54.83
+28.7%
-10.1%$1.20B$166.02M-13.741,018Positive News

Related Companies and Tools


This page (NYSE:BVS) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners